Infectologia
Opinião | Covid-19: vacina Sputnik decola, graças ao impulso da revista Lancet.
7 Mai, 2021 | 10:46hCovid-19: Sputnik vaccine rockets, thanks to Lancet boost – The BMJ
Comentário no Twitter
Journals risk being used in place of regulators when they publish studies of novel vaccines that have not yet been authorised by a major regulator @DoctorChrisVT unpicks the story of the Sputnik V vaccine https://t.co/lYf7l0lXcy
— The BMJ (@bmj_latest) May 6, 2021
O enigma COVID-19: decifrando a fisiopatologia e os fenótipos de uma nova doença.
7 Mai, 2021 | 10:44h
Comentário no Twitter
We forget that covid-19 is a new disease, never having been seen until late 2019, w/ different features than any prior illness. A truly outstanding review today on its pathophysiology https://t.co/8gx2w8r1xf @LancetRespirMed @osuchm and colleagues pic.twitter.com/WGIfI2nb9B
— Eric Topol (@EricTopol) May 6, 2021
Diretrizes Clínicas do CDC para diagnóstico e tratamento de botulismo, 2021.
7 Mai, 2021 | 10:43h
Comentário no Twitter
New CDC guidelines on botulism, the first botulism clinical guidelines are excellent.
🔑 points:
1) high clinical suspicion needed
2) BAT should be given in first 24 hours but can give later if progression of paralysis
3) Retreatment not recommended https://t.co/AfhrB74G0d— Joseph Marcus (@JosephMarcusID) May 7, 2021
Estudo randomizado: A terapia profilática de feridas utilizando-se pressão negativa em incisão fechada reduz (diferença próxima de significância estatística; P = 0,06) o risco de infecção no local da cirurgia em mulheres obesas submetidas a parto cesariano.
7 Mai, 2021 | 10:37hEm ação surpreendente, EUA se posiciona a favor da liberação de patentes das vacinas contra COVID. “A administração Biden atrai aplausos dos pesquisadores em saúde pública e irrita a indústria farmacêutica.”
6 Mai, 2021 | 07:49hIn shock move, US backs waiving patents on COVID vaccines – Nature
Ver também: U.S. will back proposal to waive intellectual property rights and boost Covid-19 vaccine production – STAT E Statement from the Executive Director of UNAIDS, Winnie Byanyima on the decision by the United States of America to support the TRIPS waiver for COVID-19 vaccines – UNAIDS E WHO Director-General commends United States decision to support temporary waiver on intellectual property rights for COVID-19 vaccines – World Health Organization
Comentário no Twitter
These extraordinary times and circumstances of call for extraordinary measures.
The US supports the waiver of IP protections on COVID-19 vaccines to help end the pandemic and we’ll actively participate in @WTO negotiations to make that happen. pic.twitter.com/96ERlboZS8
— Ambassador Katherine Tai (@AmbassadorTai) May 5, 2021
Estudo randomizado: Vacina Novavax é 49,4% eficaz contra a variante B.1.351 do SARS-CoV-2.
6 Mai, 2021 | 07:46hEstudo observacional no Catar: Vacina da Pfizer–BioNTech se mostrou 89,5% eficaz contra a variante B.1.1.7 e 75% eficaz contra a variante B.1.351. A eficácia da vacina contra doença grave, crítica ou fatal com qualquer variante do SARS-CoV-2 foi de 97,4%.
6 Mai, 2021 | 07:45h
Comentário no Twitter
📍GET BOTH DOSES! Great variants & #COVID19 vaccine news—Pfizer/BioNTech vaccine had great efficacy of 89.5% vs #B117 🇬🇧 variant & 75% vs #B1351 🇿🇦 variant for infection—but only with 2 doses. The 1 dose efficacy was just ~29% vs #B117 & ~17% vs #B1351. 🧵https://t.co/SprUfggnmh pic.twitter.com/VDWHiLsQLL
— Eric Feigl-Ding (@DrEricDing) May 6, 2021
Estudo observacional em Israel: vacina da Pfizer-BioNTech é 95,3% eficaz contra a infecção por SARS-CoV-2.
6 Mai, 2021 | 07:43hComentários: Expert reaction to Israel nation-wide study looking at Pfizer vaccine effectiveness – Science Media Centre E Covid-19: Two doses of Pfizer vaccine are “highly effective” against infection, hospital admission, and death, study finds – The BMJ
Receptores de transplante de órgãos continuam vulneráveis à Covid-19 mesmo depois da segunda dose da vacina.
6 Mai, 2021 | 07:42hEstudo Original: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients – JAMA
Estudo de coorte mostra resposta imunológica inadequada à vacina de mRNA do SARS-CoV-2 entre receptores de transplante renal.
6 Mai, 2021 | 07:40h
Comentário no Twitter
The studies of mRNA vax in people with transplants are getting bigger: still the same message. Some protection, but not enough. This time, 308 people with kidney transplants in Israel, BNT-Pfizer vaccine https://t.co/Otvt8F11my
— Hilda Bastian, PhD (@hildabast) May 6, 2021